WCM
ACAD icon

WealthBridge Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

WealthBridge Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-670
Closed -$17K – 113
2019
Q1 		$17K Sell
670
-143
-18% -$3.34K 0.01% 463
2018
Q4 		$13K Buy
+813
New +$15.8K 0.01% 476

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

WealthBridge Capital Management's ACAD Position: Q2 2019 in Review

WealthBridge Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2019, closing a stake of 670 shares — an estimated $17K sold.

WealthBridge Capital Management first reported a position in ACAD in Q4 2018 and held it in 2 quarters. The position peaked at $17K in Q1 2019. 196 funds tracked by Wall St. Rank hold ACAD as of Q2 2019.

  • WealthBridge Capital Management reported no remaining Acadia Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • WealthBridge Capital Management sold 670 Acadia Pharmaceuticals shares in Q2 2019, an estimated $17K.
  • WealthBridge Capital Management first reported a position in Acadia Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • WealthBridge Capital Management's Acadia Pharmaceuticals position peaked at $17K in Q1 2019.
  • 196 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2019.

Based on WealthBridge Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.